2-Ethenyl-1-(2-methylpropyl)imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-Ethenyl-1-(2-methylpropyl)imidazole
• 英文别名: 2-ethenyl-1-(2-methylpropyl)imidazole
• 化学式: C₉H₁₄N₂
• 分子量: 150.22
• InChiKey: XNMQRAVYFPDTMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• HCV PROTEASE INHIBITORS AND USES THEREOF
  申请人：Celgene Avilomics Research, Inc.

  公开号：US20160235805A1

  公开（公告）日：2016-08-18

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供化合物、药学上可接受的组合物以及使用它们的方法。
• Substituted 2,4-diaminopyrimidines as kinase inhibitors
  申请人：Celgene CAR LLC

  公开号：US10828300B2

  公开（公告）日：2020-11-10

  The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.

  本发明提供了作为激酶抑制剂的 2,4-二氨基嘧啶和/或其药学上可接受的组合物。
• Compositions and methods for treating cancer
  申请人：The Regents of the University of California

  公开号：US11008334B2

  公开（公告）日：2021-05-18

  K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

  K-Ras 是人类癌症中最常见的突变癌基因。本文公开了调节 K-Ras 和治疗癌症的组合物和方法。
• HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Celgene CAR LLC

  公开号：US20190117650A1

  公开（公告）日：2019-04-25

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
• COMPOSITIONS AND METHODS FOR TREATING CANCER
  申请人：The Regents of the University of California

  公开号：US20200255446A1

  公开（公告）日：2020-08-13

  K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.